Signing of an exclusive Licensing Agreement with Ripple Therapeutics Corp.
Théa Open Innovation signs an exclusive Licensing Agreement for the rights on Ripple Therapeutics Corporation lead product, IBE-814 for North America and Europe.
©Zhiguo He
Théa Open Innovation signs an exclusive Licensing Agreement for the rights on Ripple Therapeutics Corporation lead product, IBE-814 for North America and Europe.
OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases.